Near-infrared contrast agent reveals microcalcifications related to breast and bone cancer

Near-infrared fluorescence mammography works with rays of near-infrared (NIR) light instead of X-rays. Although this is thought to be a very promising technique, there have been no effective contrast agents.

However, John V Frangioni and team at the Beth Israel Deaconess Medical Centre of Harvard Medical School in Boston, Mass., have developed a contrast agent that shows up microcalcifications related to malignant breast tumours. The researchers report in the Angewandte Chemie International Edition 2007, that in validation trials using pigs, their new contrast agent distinguishes specific calcium salts in soft tissues and depicts bones. 
The researchers used the drug pamidronate (a biophosphonate, used to treat osteoporosis and bone metastases in breast cancer) as the basis of their NIR contrast agent. To this they attached a dye that absorbs light and fluoresces in the NIR region of the spectrum. Light in this region of the spectrum penetrates live tissue particularly well and without damage; it is also easy to detect.
Due to the development by Kumar R Bhushan of a simplified, reliable synthetic route to a new pamidronate derivative, the team has synthesised enough of a Pam800 contrast agent to run a trial with large animals. (Intravenously injected Pam800 shows up pig bones with very high sensitivity). When hydroxyapatite is injected into soft tissues, the contrast agent marks only the tiny hydroxyapatite crystals with high selectivity and sensitivity, which could allow it to selectively reveal malignant abnormal tissue, the team point out. The pig trials demonstrated that the use of real-time NIR fluorescence images could even enable image-guided surgery on soft tissues and bones.


More on the subject:
Read all latest stories

Related articles


News • Tumor identification in CUP patients

Cancer of unknown primary: comprehensive molecular analysis can improve therapy

A considerable proportion of patients suffering from cancer of unknown primary (CUP) could benefit from comprehensive molecular analysis and molecularly-informed targeted therapies.


News • AI approach to colorectal tumors

Deep learning identifies molecular patterns of cancer

A new AI platform can analyze genomic data extremely quickly, picking out key patterns to classify different types of colorectal tumors and improve the drug discovery process.


Sponsored • Liquid handling

Revolutionising Molecular Diagnostics With PurePrep TTR

With micro-organisms and viruses constantly developing, mutating, and evolving, diagnostics must adapt just as rapidly. Advanced laboratory technology and instruments are undeniably a prerequisite…

Related products

Sense Biodetection, Ltd. - Veros Covid-19


Sense Biodetection, Ltd. - Veros Covid-19

Sense Biodetection, Ltd.
Siemens Healthineers – Biograph mMR


Siemens Healthineers – Biograph mMR

Siemens Healthineers
Subscribe to Newsletter